摘要
目的:探讨冷消融联合中药模式治疗老年晚期非小细胞肺癌(NSCLC)患者的疗效能否达到常规化疗水平。方法:采用多中心回顾性队列研究方法,选取2014年1月1日至2018年12月31日北京医院、河北医科大学第四附属医院、北京中医医院、湖北省中医院等4家大型中、西医医院原发性肺癌住院患者作为研究对象,按照不同暴露因素分为常规化疗队列220例和冷消融联合中药队列96例,采用倾向评分匹配(PSM)使得基线具有可比性,匹配成功87对并比较2组生存期、生命质量、实体瘤疗效评价和安全性。结果:冷消融联合中药队列相比化疗队列在延长患者中位无进展生存期(PFS),增强近期疗效,提高患者生命质量方面优于常规化疗(均P<0.05),在总体生存获益方面与化疗相当(P>0.05)。结论:冷消融联合中药模式治疗老年晚期NSCLC患者在延缓病情进展、增强近期疗效、提高患者生命质量方面优于常规化疗,在总体生存获益方面与化疗相当,可以作为老年晚期NSCLC患者的新的治疗选择。
Objective:To investigate whether the efficacy of cold ablation combined with traditional Chinese medicine(TCM)modality in treating elderly patients with advanced non-small cell lung cancer(NSCLC)can reach the level of conventional chemotherapy.Methods:A multicenter retrospective cohort study was performed in Beijing Hospital,the Fourth Hospital of Hebei Medical University,Beijing Hospital of Traditional Chinese Medicine,Hubei Provincial Hospital of Traditional Chinese Medicine,and four other large TCM and Western hospitals from January 1,2014 to December 31,2018.Inpatients with primary lung cancer were selected as the study subjects.According to different exposure factors,220 patients were divided into the conventional chemotherapy cohort,and 96 patients were divided into the cold ablation combined with the TCM cohort.Propensity score matching(PSM)was used to make the baseline comparable,and 87 pairs were successfully matched.Then,the survival time,life quality,solid tumor response evaluation,and safety were compared between the two cohorts.Results:Compared with the chemotherapy cohort,the cold ablation combined with the TCM cohort was better in prolonging patients′median progression free survival(PFS)time,enhancing near-term efficacy,and improving patients′life quality(P<0.05),while it was comparable to chemotherapy in overall survival benefit(P>0.05).Conclusion:Cold ablation combined with TCM modality in treating elderly patients with advanced NSCLC is superior to conventional chemotherapy in delaying disease progression,enhancing near-term efficacy,and improving patients′life quality,and is comparable to chemotherapy in overall survival benefit.It can be used as a new treatment option for elderly patients with NSCLC.
作者
王剑锋
周天
别志欣
胡凯文
WANG Jianfeng;ZHOU Tian;BIE Zhixin;HU Kaiwen(Guang′anmen Hospital,Chinese Academy of Chinese Medical Sciences,Beijing 100053,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;Beijing Hospital,Beijing 100005)
出处
《世界中医药》
北大核心
2025年第7期1188-1194,共7页
World Chinese Medicine
基金
国家重点研发计划项目(2018YFC1705102)。
关键词
冷消融
中药
化疗
老年
晚期
非小细胞肺癌
队列研究
疗效
安全性
Cold ablation
Traditional Chinese medicine
Chemotherapy
Elderly
Advanced
Non-small cell lung cancer
Cohort study
Efficacy
Safety
